|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Sections of Infectious Diseases, Medical
Oncology, Hematology, and Nephrology and the Departments of Medicine,
Immunobiology, and Laboratory Medicine, Yale School of Medicine, New
Haven, CT; and the University of Minnesota Cancer Center, the
Department of Pediatrics, and the Division of Blood and Marrow
Transplantation, Minneapolis, MN.
Epstein-Barr virus (EBV)-specific CD8 T lymphocytes are present at
remarkably high frequencies in healthy EBV+
individuals and provide protection from EBV-associated
lymphoproliferative diseases. Allogeneic peripheral blood stem cell
transplantation (allo-PBSCT) is a commonly used therapy in which T-cell
surveillance for EBV is temporarily disrupted. Herein, human leukocyte
antigen (HLA) class I tetramers were used to investigate the
reestablishment of the EBV-specific CD8 T-cell repertoire in patients
following allo-PBSCT. CD8+ T cells specific for lytic and
latent cycle-derived EBV peptides rapidly repopulate the periphery of
matched sibling allo-PBSCT patients. The relative frequencies of T
cells specific for different EBV peptides in transplantation recipients
closely reflect those of their respective donors. Investigation of
patients at monthly intervals following unmanipulated allo-PBSCT
demonstrated that the frequency of EBV-specific T cells correlates with
the number of EBV genome copies in the peripheral blood and that
expansion of EBV-specific T-cell populations occurs even in the
setting of immunosuppressive therapy. In contrast, patients undergoing T-cell-depleted or unrelated cord blood transplantation have
undetectable EBV-specific T cells, even in the presence of Epstein-Barr
viremia. The protective shield provided by EBV-specific CD8 T cells is rapidly established following unmanipulated matched sibling allo-PBSCT and demonstrates that HLA class I tetramers complexed with viral peptides can provide direct and rapid assessment of pathogen-specific immunity in this and other vulnerable patient populations.
(Blood. 2000;96:2814-2821) Allogeneic peripheral blood stem cell
transplantation (allo-PBSCT) is a lifesaving therapy for neoplastic and
genetic hematologic diseases1 and is increasingly used to
treat autoimmune diseases.2,3 Graft-versus-host disease
(GVHD), an alloimmune attack on host tissues mediated by donor T cells,
is a major complication of allo-PBSCT. Measures to limit or prevent
GVHD include (1) pharmacologic immunosuppression with T-cell inhibitory
drugs such as cyclosporin A or tacrolimus4,5; (2) in vivo
depletion of T cells in the transplant recipient with antibodies that
recognize the lymphocyte surface protein CD52 (CAMPATH-1) or other
T-cell-specific surface proteins (antithymocyte globulin
[ATG])6,7; and (3) ex vivo depletion of T lymphocytes
from the allograft prior to infusion into the transplant recipient.
Although these methods can be effective at modulating or ameliorating
GVHD, they are associated with the second major complication of
allografting, a heightened susceptibility to infection. Epstein-Barr
virus (EBV) is one among a panoply of pathogens that can cause severe
complications in immunosuppressed patients.8
EBV causes persistent infection of B lymphocytes in greater than
90% of healthy adults.9 Infection of human B lymphocytes with EBV results in their transformation, and EBV-specific T cells play
a central role in preventing their uncontrolled growth. Compromise of
cell-mediated immunity results in a spectrum of lymphoproliferative diseases ranging from polyclonal lymphoid hyperplasia to rapidly fatal
malignant monoclonal lymphomas.10 These diseases are found in people with acquired and congenital immunodeficiencies and in solid
organ or bone marrow transplantation patients. Major histocompatability
complex (MHC) class I molecules on the surface of EBV-transformed B
lymphocytes present virally derived peptides to CD8+
cytotoxic T lymphocytes (CTLs), a process that appears to be vital for
the control of latent EBV infection in healthy EBV+
individuals.9 Recipients of T-cell-depleted stem cell or
solid organ allografts or those who require immunosuppression to treat GVHD are at risk for EBV-associated posttransplantation
lymphoproliferative disease (PTLD).8
Evidence of the role of CD8+ CTLs in controlling
viral infections following allogeneic bone marrow transplantation
(allo-BMT) comes from adoptive transfer studies. Riddell and
colleagues11 generated cytomegalovirus
(CMV)-specific CTL clones and infused them into allo-BMT recipients.
Transferred T cells persisted for several months, and none of the
recipients developed fatal CMV disease. Papadopoulos et
al12 transferred unmanipulated donor lymphocytes into
T-cell-depleted allo-BMT recipients and eradicated PTLD. Along similar
lines, Rooney et al13 transferred EBV-specific polyclonal T
cell lines into patients, which lead to regression of PTLD.
Recently, MHC class I tetramers have been developed as reagents to
identify antigen-specific T lymphocytes. Tetramers consist of 4 identical MHC class I peptide complexes that are bound to a
fluorochrome-conjugated streptavidin molecule. Our ability to measure
and characterize virus- and bacteria-specific T-cell populations during
the course of acute and chronic infections has been greatly advanced by
this new technology.14-18 Quantitative studies using MHC
class I tetramers complexed with peptides derived from latent and lytic
cycle EBV proteins have demonstrated that primary EBV infection is
accompanied by a massive expansion of virus-specific CD8 T-cell
populations, with up to 40% of CD8+ T cells responding to
one epitope.19 Remarkably, in healthy EBV+
individuals, up to 5% of CD8 T cells are specific for EBV even years
following primary infection.20 The impact of
immunosuppressive therapy on EBV-specific T-cell populations and the
kinetics of EBV-specific T-lymphocyte reconstitution in patients
undergoing allo-PBSCT has not been determined with this methodology.
In this report we investigate PBSCT recipients, measuring the
redevelopment of the EBV-specific T-cell repertoire within the CD8
T-cell compartment. Using a broad panel of human leukocyte antigen
(HLA)-A2, HLA-B8, and HLA-B7 tetramers complexed with multiple latent
and lytic EBV peptides, we show that EBV-specific T cells form a
substantial percentage of CD8 T cells within one month of
transplantation. The frequency and absolute number of T cells that are
specific for lytic EBV peptides correlate directly with the in vivo
viral load, even in the face of aggressive immunosuppression. Our
studies demonstrate the feasibility of monitoring EBV-specific CTLs in
allo-PBSCT recipients and suggest that tetramer analysis may enable
rapid and direct identification of individuals at risk of PTLD.
Human subjects
Patient conditioning
Cell lines Lymphoblastoid cell lines (B-LCLs) were established from healthy donors AD, EA, EP, and KK. PBMCs were isolated from heparinized blood on lymphocyte separation medium (ICN Biomedicals, Aurora, OH), and EBV-transformed B-LCLs were generated by incubation with the B95-8 EBV strain (Dr George Miller, Yale University) in the presence of 1 nmol/L tacrolimus. B-LCLs were maintained in Roswell Park Memorial Institute (RPMI) media supplemented with 10% fetal calf serum (FCS). EBV-specific T cell lines were generated by stimulating 1-2.5 × 107 Ficoll-purified PBMCs with 5-7.5 × 106 irradiated autologous B-LCLs. T cell lines were maintained by weekly restimulation with autologous B-LCLs. After the second restimulation T-cell cultures were supplemented with 5% human phytohemagglutinin (PHA) T stim (Becton Dickinson, San Jose, CA).Generation of HLA-A2, HLA-B7, and HLA-B8 tetramers Tetrameric HLA-A2, HLA-B7, and HLA-B8 complexes were generated with human 2-microglobulin and EBV peptides using previously described methods. Materials used included the plasmid construct expressing HLA-A2 with a biotinylation signal (Coulter, Miami, FL), the
construct for HLA-B8 (John Altman, Emory University, Atlanta, GA), and
complementary DNA (cDNA) for HLA-B7 (Peter Parham, Stanford University,
Palo Alto, CA). The cDNA was used as a template for polymerase chain
reaction (PCR) mutagenesis, which eliminated the signal sequence and
replaced the transmembrane and cytoplasmic regions with a biotinylation
sequence, as previously described,21,22 using the
following primers:
5'-CATGCCATGGATACCATTCCATGAGGTATTTCTACACC-3' and
5'-CTAGCTAGCGGACTGGGAAGACGGCTCCCA-3'. The PCR product was cloned into
the PET 21d vector (Novagen, Madison, WI), and recombinant proteins
were generated as insoluble proteins following induction with IPTG in
Escherichia coli strain BL21 (DE3) LysS and purified as
previously described. Insoluble HLA-A2, HLA-B7, and HLA-B8 and human
2-microglobulin were dissolved in 8 mol/L urea and refolded
in the presence of 25 µg/mL of the appropriate peptide with the
following protease inhibitors: 1 µg/mL pepstatin A, 1 µg/mL
leupeptin, and 0.4 mmol/L phenylmethylsulfonyl fluoride (PMSF). The
following peptides (Research Genetics, Huntsville, AL) were used in the
generation of tetramers: GLCTLVAML, CLGGLLTMV, and LLDFVRFMGV
(HLA-A2-restricted epitopes); RPPIFIRRL and VPAPAGPIV (HLA-B7-restricted epitopes); and RAKFKQLL, QAKWRLQTL, and FLRGRAYGL (HLA-B8-restricted epitopes). Soluble monomeric complexes were purified by gel filtration over a Superdex 200HR column (Amersham Pharmacia Biotech). Purified monomeric complexes were biotinylated at
room temperature for 12 hours in the presence of 15 µg Bir A enzyme
(Avidity, Boulder, CO), 80 µmol/L biotin, 10 mmol/L adenosine 5'-triphosphate (ATP), 10 mmol/L MgOAc, and 20 mmol/L bicine; purified
by gel filtration to remove excess biotin; and then tetramerized with
phycoerythrin (PE)-conjugated streptavidin (Molecular Probes, Sunnyvale, CA) at a 4:1 molar ratio. Finally, tetramers were purified by gel filtration and stored at 4°C in phosphate-buffered saline (PBS) (pH 8.0) with 0.02% sodium azide, 1 µmol pepstatin, 1 µg/mL leupeptin, and 0.5 mmol/L ethylenediamine tetraacetic acid (EDTA).
Cell staining Fresh PBMCs or cell lines generated from healthy individuals, stem cell allograft recipients, or renal allograft recipients were incubated on ice for 1 hour in staining buffer (comprising PBS with 0.5% bovine serum albumin [BSA] and 0.02% sodium azide [pH 7.45]) containing (1) 0.25-0.5 mg/mL PE-labeled tetrameric complex; (2) saturating amounts of anti-CD3 and anti-CD8 mAbs conjugated to APC (Immunotech International, Marseilles, France) or Cychrome (PharMingen, San Diego, CA); and (3) either anti-CD44, anti-CD45RA, or anti-CD62L-FITC (fluorescein isothiocyanate) (Immunotech). The stained cells were fixed in 1% paraformaldehyde and analyzed by a fluorescence-activated cell sorter (FACS) using CellQuest software (Becton Dickinson). Lymphocytes were gated by forward and side angle light scatter.EBV quantitative PCR Blood was drawn into EDTA-containing tubes and processed on the same day. Mononuclear cells were purified on lymphocyte separation medium and the cells were treated with 60 µg/mL proteinase K (Roche Molecular Biochemicals, Indianapolis, IN). DNA from aliquots of 100 000 cells was amplified using primers 1100 and 1181 (Operon, Alameda, CA) for the EBV BMLF1 gene.23 The 50 µL PCR reaction components (Roche Molecular Biochemicals) included 10 times PCR buffer; 1.5 mmol/L MgCl2; 0.025 µmol/L each of adenosine, cytadine, guanosine, and uridine 5'-triphosphate (dATP, dCTP, dGTP, and dUTP, respectively); and 1.0 U Taq DNA polymerase. The EBV-containing Raji cell line (50 EBV genomes per cell) was used to develop a standard curve. Thermal cycle parameters were completed for 35 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute in a Perkin-Elmer 9600 thermal cycler (Perkin Elmer). The PCR product was hybridized to a BMLF 1 probe (10 pm) labeled with Tris (tris[hydroxymethyl] aminomethane; 2, 2'-bipyridine) rutherium II chelate (TBR) electrochemiluminescent label (Baron Biotech, Milford, CT).24 The hybridized PCR product was quantified using a Perkin Elmer QPCR 5000. All patient samples were amplified using-globin primers to test for DNA integrity.
As a first step toward investigating EBV-specific T-cell
populations in patients undergoing allo-PBSCT, we generated an HLA tetramer panel with 3 different HLA class I molecules, each complexed with multiple antigenic EBV-derived peptides (Table
2). In addition to HLA-A2 and HLA-B8
tetramers, which have been used previously to measure EBV-specific
T-cell populations in patients during and following acute EBV
infection, our panel also included HLA-B7 tetramers complexed with 2 EBV peptides and HLA-A2 and HLA-B8 tetramers complexed with additional
antigenic EBV peptides. To determine the specificity of our tetramer
panel, we generated EBV-specific T cell lines from healthy
EBV+ individuals by in vitro restimulation of fresh PBMCs
with autologous B-LCLs. T cell lines were stained with mAbs specific
for CD8 and CD62L and with HLA tetramers complexed with EBV peptides
(Figure 1). Staining of a T cell line
derived from individual AD (who expresses HLA-A2) demonstrates that
11.7% of CD8-gated T lymphocytes bound HLA-A2 tetramers complexed with
a peptide derived from the lytic BMLF1 protein (Figure 1, upper left
panel), and 6.21% and 0.4% of CD8 T cells bound HLA-A2 tetramers
complexed with peptides derived from the latent EBNA3C and LMP2
proteins (Figure 1, upper middle and right panels).
T cell lines generated from HLA-A2 To confirm the feasibility of tetramer staining for the direct analysis
of EBV-specific T cells in peripheral blood, we isolated PBMCs from 4 healthy EBV+ individuals and stained cells with our panel
of MHC class I tetramers. In individual KK, who expresses HLA-A2,
approximately 1.5% of the CD8 T cells stained with HLA-A2 tetramers
complexed with the lytic protein BMLF1 peptide; tetramers complexed
with the latent protein EBNA3C and LMP2 peptides did not stain
detectable CD8 T-cell populations (Figure
2, upper panels). Individuals EA and EP,
who express HLA-B8, had readily detectable CD8 T-cell populations that
stained HLA-B8 tetramers complexed with the lytic protein BZLF1 peptide
(2.1%) and 2 latent protein EBNA3A peptides (2.3% and 0.68%).
Staining of PBMCs from individual KK, who also expresses HLA-B7,
demonstrated that approximately 0.28% of CD8 T cells bound HLA-B7
tetramers complexed with one of the latent protein EBNA3A peptides; the
binding of tetramers complexed with a second EBNA3A peptide was
undetectable (Figure 2, lower panels).
These analyses demonstrate that HLA tetramers complexed with EBV-derived peptides can directly identify EBV-specific CD8 T cells ex vivo from healthy individuals. All of our tetramers were tested for the staining of PBMCs isolated from individuals not expressing the particular MHC class I molecule. All were negative, confirming once again the specificity of these reagents (results not shown). Additionally, in these and subsequent analyses, staining with antibodies specific for CD3 (which is only expressed on T cells) and CD56 (a natural killer cell marker) revealed that tetramer-staining cells were CD3+ T cells and not natural killer cells. EBV-specific CD8 T cells identified by HLA tetramer staining generally fell into 2 subpopulations that expressed either high or low levels of CD62L, an adhesion molecule that is down-regulated on the cell surface upon T-cell activation. This pattern of expression of CD62L has been described previously for EBV-specific T cells in EBV+ individuals.20 To determine whether allo-PBSCT recipients regenerate EBV-specific
T-cell populations that are similar in magnitude to healthy individuals, we next evaluated 2 patients who had undergone matched sibling donor (MSD) allogeneic PBSCT. The clinical characteristics of
the patients included in this study and the HLA typing of the patients
and donors are summarized in Table 2. CD8 T cells from patient
A, who expresses HLA-B8 and underwent allo-PBSCT 5 months prior to this
analysis, are shown in Figure 3A.
Approximately 0.9% of CD8 T cells stained with HLA-B8 tetramers
complexed with the lytic BZLF1 peptide, and 0.3% and 0.62% of CD8 T
cells were specific for the 2 latent EBNA3A-derived peptides (Figure
3A). EBV-specific CD8 T cells from patient B, who expresses HLA-A2 and
underwent transplantation 9 months prior to analysis, are shown in
Figure 3B. Nearly 7% of CD8 T cells in this patient are specific for
the HLA-A2 restricted lytic BMLF1-derived peptide. Phenotypic analysis
of the tetramer-positive cells revealed that the population is split
between CD45RA+ and CD45RA
Although the previous analyses demonstrated that allo-PBSCT recipients
generate EBV-specific T-cell populations, it was unclear how rapidly
EBV-specific immunity redeveloped following transplantation. Therefore,
we next investigated patient C, who expresses HLA-A2 and HLA-B8 at
monthly intervals following allo-PBSCT. Remarkably, 30 days following
transplantation, 2.68% of the CD8 T cells stained with HLA-B8
tetramers complexed with the lytic BZLF1 peptide (Figure 4). In contrast, HLA-B8-restricted CD8 T
cells specific for the EBNA3A peptide or HLA-A2-restricted T cells
specific for a BMLF1 peptide were present at 20- to 30-fold lower
frequencies. Analysis of patient C 60 days following transplantation
demonstrated a dramatic expansion of EBV-specific CD8 T cells specific
for HLA-B8/BZLF1 (12.67%), HLA-B8/EBNA3A (1.94%), and HLA-A2/BMLF1
(2.91%). Of note, patient C developed GVHD of the skin and
gastrointestinal tract 30 days following transplantation, which
required, in addition to tacrolimus, immunosuppression with
steroids and eventually antithymocyte globulin. In spite of this
immunosuppressive regimen, patient C had a substantial expansion of
EBV-specific T cells, both in frequency (Figure 4) and absolute number
in terms of EBV-specific T cells per µL of blood (Figure
5). Patient C's GVHD stabilized in the
following months, after which his immunosuppression was gradually
tapered, and the frequency of EBV-specific T cells decreased 90 and 120 days following transplantation (Figure 4).
To correlate the frequency of EBV-specific T cells with the EBV viral load, we used HLA tetramers to measure the frequency of EBV-specific CD8 T cells and PCR to determine the number of EBV genomes per 105 PBMCs at monthly intervals in 3 patients following allo-PBSCT. This quantitative analysis revealed that patient C had a dramatic increase in the number of EBV genomes 60 days following transplantation, at the same time that the EBV-specific T-cell population underwent expansion (Figure 5, upper panel). Despite aggressive immunosuppression, the EBV load dropped precipitously 90 days following transplantation and was accompanied by a similar decrease in the number of EBV-specific CD8 T lymphocytes. Interestingly, although the number of EBV-specific CD8 T cells increased and then decreased following transplantation, the patient's CD8 T-cell count decreased between days 30 and 120 following treatment for GVHD. Although the decrease in CD8 T-cell numbers can be attributed to antithymocyte globulin and steroid administration, the relative insensitivity of EBV-specific T cells is remarkable. The EBV-specific T-cell number, CD8+ T-cell absolute number, and EBV genome titer for patients D and E, who are both HLA-A2, were less dramatic (Figure 5, middle and lower panels). Patients D and E, who received steroids for GVHD, did not have an increase in EBV genome numbers, and both the EBV-specific and total CD8+ T-cell numbers remained stable throughout the duration of follow-up. Different peptides derived from single pathogens are known to elicit
T-cell responses that differ in size.25,26 The factors responsible for the T-cell hierarchies include antigen stability; T-cell repertoire; and to a lesser extent, antigen
prevalence.27-30 We decided to compare the hierarchy of
T-cell responses to EBV epitopes in recipients of allo-PBSCT and their
donors following reconstitution of the T-cell compartment. We
determined the frequency of EBV-specific T cells to 3 HLA-A2- and 3 HLA-B8-restricted EBV epitopes in patients A, B, C, D, and E and in
their respective stem cell donors. This analysis revealed that although
not identical, the relative frequencies of T cells specific for the
different EBV epitopes are similar in the donor and recipient (Figure
6). In some instances, such as the
HLA-A2/BMLF1-specific T-cell populations in the patient B/donor pair,
the frequencies appear to be disparate, but the overall patterns
suggest a similarity between the recipients and their donors. In
contrast, comparison of the T-cell hierarchies between different
recipient/donor pairs indicates a higher degree of disparity (eg,
compare hierarchies of HLA-A2 patients B and D). At a quantitative
level, these results suggest that the homeostatic mechanisms
determining the frequency and hierarchy of virus-specific T cells in
the healthy donor have been recapitulated in the matched sibling stem
cell allograft recipient.
Solid organ transplant recipients or patients with HLA disparity
undergoing PBSCT are at higher risk for PTLD when compared to MSD stem
cell allograft recipients. We performed a preliminary study of patients
undergoing unrelated UCB, MUD, or haploidentical (HAPLO) stem cell
transplantation or solid organ transplantation (Table
3). Of the 5 solid organ allograft
recipients, 4 recipients had detectable populations of EBV-specific T
cells and a normal EBV genome titer. Patient YS-5 had no detectable
EBV-specific T cells and a high EBV genome titer. We are currently
following this patient to evaluate for the development of EBV-specific
CD8 T cells. We studied 4 patients who received unrelated UCB
transplantations, 1 patient who received a non-T-cell-depleted MUD
transplantation, and 1 patient who received a HAPLO allograft. We did
not detect EBV-specific T cells in any of these stem cell allograft
recipients. Although EBV viral titers were not elevated in the UCB or
HAPLO recipients, the patient who received a MUD transplantation (M-4) had an EBV genome titer of 176.
The recent introduction of methods that directly identify antigen-specific T lymphocytes has provided unprecedented views of the interaction between the human immune system and infectious pathogens.14,18 In this report we have used MHC class I tetramers to characterize the dynamics of EBV-specific T lymphocytes in patients undergoing one of the most dramatic immunomodulatory therapies in current medical practice: immune ablation followed by allogeneic stem cell transplantation. In the face of this upheaval within the patient's immune system, we find that EBV-specific CD8 T-cell populations are readily detectable in patients following matched sibling allo-PBSCT and in solid organ transplant recipients, and their frequencies rapidly approximate those found in healthy individuals. Despite potent immunosuppressive therapy to prevent GVHD, the reconstitution of EBV-specific immunity is rapid and effective. In a patient analyzed at monthly intervals following transplantation, the frequency of EBV-specific T lymphocytes correlated with the amount of EBV detected by PCR in PBMCs. This suggests that EBV-specific T-cell populations expanded in response to the increased viral burden even while the number of CD8 T cells declined. Our finding that the frequency of EBV-specific CD8 T cells correlates with the abundance of EBV genomes is reminiscent of human immunodeficiency virus (HIV)-specific CD8 T-cell populations in patients treated with antiretroviral therapy. In adults and children receiving highly active antiretroviral therapy (HAART), dramatic reductions in viral load were associated with decreased HIV-specific CTL frequencies,14,31 suggesting that the size of antigen-specific T-cell populations in the setting of chronic infections is determined by antigen prevalence. A similar correlation between the prevalence of viral antigen and the frequency of HIV-specific T lymphocytes has also been demonstrated in the CD4+ T-cell compartment.32 Thus, although there is abundant evidence that pathogen-specific T lymphocytes play a critical role in the suppression of chronic viral infections, our study and those performed in HIV-infected individuals demonstrate that the relative activity of viral infection dramatically influences the frequency of virus-specific T lymphocytes in the peripheral blood. UCB allografts are EBV The reconstitution of EBV-specific T-cell populations was carefully investigated in the pretetramer era. Using limiting dilution analysis, which we now know substantially underestimates the true frequency of antigen-specific T lymphocytes, Lucas et al35 demonstrated that EBV-specific T cells were present 3 months following BMT in normal frequencies in 19% of the patients, in intermediate frequencies in 23%, and undetectable in 58%. That study, which measured the frequency of T cells responding to B-LCLs, did not differentiate between T cells specific for lytic or latent cycle EBV proteins. Surprisingly, the size of EBV-specific T-cell populations measured by limiting dilution did not differ detectably between patients receiving unmanipulated bone marrow grafts and those receiving T-cell-depleted grafts. Haque et al36 evaluated the frequency of EBV-specific CTLs in solid organ recipients before and after EBV-specific CTL infusions using limiting dilution analysis. In the few patients studied, they detected very low levels of EBV CTL pre-infusion in one patient but none in the other patients studied. After treatment with autologous EBV-specific CTL lines, the precursor frequency increased after the third infusion and correlated inversely with the EBV viral load. Peripheral blood stem cell allografts deliver more CD3+ T lymphocytes by 1-2 logs than traditional bone marrow allografts,37,38 and this may contribute to the rapid EBV-specific immune recovery seen in these patients. It has been argued that limiting dilution analysis does not detect all antigen-specific T cells, only those that are capable of undergoing further division.39 Thus, it is possible that many of the T cells we detected by tetramer staining are incapable of in vitro growth. However, our finding that EBV-specific T-cell populations can rapidly increase in size in response to a greater viral burden suggests that the T-cell populations we are measuring have the potential to divide in vivo. In patients receiving T-cell depleted BMT, the incidence of PTLD, which can approach 10%, is related to the degree of HLA disparity, rigorous T-cell depletion approaches that do not remove donor B cells, or the use of OKT3 or ATG.8 The adoptive transfer of donor lymphocytes has resulted in the remarkable regression of PTLD.12 T cell lines generated in vitro by restimulation of donor T lymphocytes with autologous B-LCL have also been adoptively transferred and have resulted in the regression of PTLD.13,40,41 A recent report from Gustafsson et al42 correlated EBV genome titer with prophylactic adoptive transfer of EBV-specific T cell lines. They showed that in T-cell-depleted stem cell allograft recipients, transfer of EBV-specific T cells resulted in a decrease in the viral titer and protection from PTLD. Our study confirms the finding by Callan and colleagues20 that the frequency of EBV-specific T cells in healthy EBV+ individuals is remarkably high, exceeding 5% of CD8 T cells in some individuals. The high frequency of these cells suggests that HLA tetramers may be useful for the direct purification of EBV-specific T cells. This may be used for the prophylactic supplementation of T-cell-depleted stem cell allografts or therapeutic treatment of patients with PTLD without the cost and time involved to generate EBV-specific T cell lines or the GVHD risk involved with giving unmanipulated donor lymphocyte infusions.
We would like to thank Jan Kotora, RN, and the nurses in the bone marrow unit for collection of samples and excellent care of these patients in relation to this project.
Submitted January 27, 2000; accepted June 12, 2000.
Supported by a Center of Excellence Grant from the John A. Hartford Foundation; a Swebilius Cancer Research Award; E.G.P. is the recipient of a Donaghue Investigator Award from the Donaghue Foundation of Hartford, CT.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Eric G. Pamer, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: pamere{at}mskcc.org.
1. Hoffman R, Benz E Jr, Shattil S, Furie B, Cohen H, Silberstein H. Hematology: Basic Principles and Practice 2nd ed. New York: Churchill Livingstone; 1995. 2. Exner B, Groninger J, Ildstad S. Bone marrow transplantation for therapy in autoimmune disease [review]. Stem Cells. 1997;15(suppl 1):171-176.
3.
Marmont A.
Stem cell transplantation for severe autoimmune diseases: progress and problems.
Haematologica.
1998;83:733-743
4.
Nash R, Pineiro L, Storb R, et al.
FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.
Blood.
1996;88:3634-3641 5. Storb R, Deeg H, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735[Abstract].
6.
Hale G, Zhang M, Bunjes D, et al.
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Blood.
1998;92:4581-4590 7. Merion R. Current use of polyclonal antilymphocyte antibody preparations. Transplant Proc. 1999;31:2208-2209[Medline] [Order article via Infotrieve]. 8. O'Reilly R, Small T, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216[Medline] [Order article via Infotrieve]. 9. Rickinson A, Moss D. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431[Medline] [Order article via Infotrieve]. 10. Knowles D. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200-217[Medline] [Order article via Infotrieve].
11.
Riddell S, Watanabe K, Goodrich J, Li C, Agha M, Greenberg P.
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
Science.
1992;257:238-241
12.
Papadopoulos E, Ladanyi M, Emanuel D, et al.
Infusions of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
N Engl J Med.
1994;330:1185-1191 13. Rooney C, Smith C, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13[Medline] [Order article via Infotrieve].
14.
Ogg S, Jin X, Bonhoeffer S, et al.
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
Science.
1998;279:2103-2106 15. Murali-Krishna K, Altman J, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998;8:177-187[Medline] [Order article via Infotrieve].
16.
Busch D, Pilip I, Pamer E.
Evolution of a complex TCR repertoire during primary and recall bacterial infection.
J Exp Med.
1998;188:61-70
17.
Kuroda M, Schmitz J, Barouch D, et al.
Analysis of Gag-specific cytotoxic T lymphocytes in Simian Immunodeficiency Virus-infected rhesus monkeys by cell staining with tetrameric major histocompatibility complex class I-peptide complex.
J Exp Med.
1998;187:1373-1381
18.
Altman J, Moss P, Goulder P, et al.
Phenotypic analysis of antigen specific T lymphocytes.
Science.
1996;274:94-96
19.
Callan M, Tan L, Annels N, et al.
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo.
J Exp Med.
1998;187:1395-1402
20.
Tan L, Gudgeon N, Annels N, et al.
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
J Immunol.
1999;162:1827-1835 21. Busch D, Pilip I, Vijh S, Pamer E. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity. 1998;8:353-362[Medline] [Order article via Infotrieve].
22.
Kerksiek K, Busch D, Pilip I, Allen S, Pamer E.
H2-M3 restricted T cells in bacterial infection: rapid primary but diminished memory responses.
J Exp Med.
1999;190:195-204 23. Pedneault L, Katz B, Miller G. Detection of Epstein Barr virus in the brain by the polymerase chain reaction. Ann Neurol. 1992;32:184-192[Medline] [Order article via Infotrieve]. 24. DiCesare J, Grossman B, Katz E, Picozza E, Ragusa R, Woudenberg T. A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantification. Biotechniques. 1993;15:152-157[Medline] [Order article via Infotrieve]. 25. Vijh S, Pamer E. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J Immunol. 1997;158:3366-3371[Abstract].
26.
Levitsky V, Xhang Q, Levitskaya J, Masucci M.
The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
J Exp Med.
1996;183:915-926
27.
Anton L, Snyder H, Bennink J, et al.
Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class Iassociated antigenic peptides.
J Immunol.
1998;160:4859-4868
28.
Busch D, Pamer E.
T cell affinity maturation by selective expansion following infection.
J Exp Med.
1999;189:701-710 29. Levitsky V, Otavio de Campos-Lima P, Frisan T, Masucci M. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol. 1998;61:594-601. 30. Levitsky V, Zhang Q, Levitskaya J, Kurilla M, Masucci M. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I: peptide complexes. J Immunol. 1997;159:5383-5390[Abstract]. 31. Spiegel H, DeFalcon E, Ogg G, et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis. 1999;180:359-368[Medline] [Order article via Infotrieve]. 32. Pitcher C, Quittner C, Peterson D, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525[Medline] [Order article via Infotrieve]. 33. Sirvent N, Reviron D, deLamballerie X, Michel G. First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation. Bone Marrow Transplant. 2000;25:120-121[Medline] [Order article via Infotrieve]. 34. Ohga S, Kanaya Y, Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transplant. 2000;25:209-212[Medline] [Order article via Infotrieve].
35.
Lucas K, Small T, Heller G, Dupont B, O'Reilly R.
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Blood.
1996;87:2594-2603
36.
Haque T, Amlot P, Helling N, et al.
Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.
J Immunol.
1998;160:6204-6209
37.
Korbling M, Huh Y, Durett A.
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+Thy-1 Dim CD38 |
Top
Abstract
Introduction
individuals did not
stain with HLA-A2 tetramers, confirming the specificity of these
reagents (data not shown). Similar experiments were performed with a T cell line generated from individual EP, who expresses both HLA-B8 and
HLA-B7. HLA-B8 tetramers complexed with peptide derived from the lytic
protein BZLF1 or 2 different peptides derived from the latent protein
EBNA3A labeled 68.1%, 7.4%, and 1.8% of CD8 T cells respectively,
and HLA-B7 tetramers complexed with peptide-derived EBNA3A labeled
20.1% of CD8 T cells (Figure 
) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
Blood.